Modelling the potential clinical and economic impact of universal immunisation with nirsevimab versus standard of practice for protecting all neonates and infants in their first respiratory syncytial virus season in Spain.

Autor: Gil-Prieto R; Department of Medical Specialties and Public Health, Rey Juan Carlos University, Madrid, Spain., Pérez JJ; Public Health Directorate, Murcia Region, Spain., Drago G; Market Access, Sanofi, Barcelona, Spain., Kieffer A; Global Health Economics and Value Assessment, Sanofi, Lyon, France., Roïz J; Evidera, London, UK., Kazmierska P; Evidera, London, UK., Sardesai A; Evidera, San Francisco, CA, USA., de Boisvilliers S; Evidera, Ivry-sur-Seine, France., López-Belmonte JL; Market Access, Sanofi, Calle Martínez Villergas, 52, Madrid, 28027, Spain. juanluis.lopez-belmonte@sanofi.com., Beuvelet M; Global Health Economics and Value Assessment, Sanofi, Lyon, France., Aldean JA; Paediatric Department, Hospital Costa del Sol, Marbella, Spain.

Publikováno v: BMC infectious diseases [BMC Infect Dis] 2024 Sep 06; Vol. 24 (1), pp. 924. Date of Electronic Publication: 2024 Sep 06.